Verition Fund Management
LOGC

Verition Fund Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Verition Fund Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-113,532
Closed -$262K – 3197
2021
Q4 		$262K Hold
113,532
– – ﹤0.01% 2071
2021
Q3 		$520K Sell
113,532
-94,567
-45% -$416K ﹤0.01% 1205
2021
Q2 		$924K Sell
208,099
-18,866
-8% -$96K 0.01% 836
2021
Q1 		$1.65M Sell
226,965
-2,869
-1% -$23.6K 0.02% 471
2020
Q4 		$1.75M Buy
+229,834
New +$1.54M 0.02% 402

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Verition Fund Management's LOGC Position: Q1 2022 in Review

Verition Fund Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 113,532 shares — an estimated $262K sold.

Verition Fund Management first reported a position in LOGC in Q4 2020 and held it in 5 quarters. The position peaked at $1.75M in Q4 2020. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Verition Fund Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Verition Fund Management sold 113,532 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $262K.
  • Verition Fund Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Verition Fund Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.75M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Verition Fund Management's 13F filing for Q1 2022, filed 13 May 2022.